LAURA ZITELLA: Open Payments
NPI 1265570949 · SAN FRANCISCO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,795 in 10 payments from 8 companies in 2025. Trend: 2023 $1,164 · 2024 $698 · 2025 $2,795
Consulting: $2,250Food & beverage: $545
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 1 | $1,200 |
| PFIZER INC. | 2 | $1,050 |
| ABBVIE INC. | 2 | $136 |
| Janssen Biotech, Inc. | 1 | $125 |
| GENZYME CORPORATION | 1 | $109 |
| AstraZeneca Pharmaceuticals LP | 1 | $83 |
| Ipsen Biopharmaceuticals, Inc | 1 | $76 |
| Adaptive Biotechnologies Corporation | 1 | $17 |
Products named: ELREXFIO, TECVAYLI, VENCLEXTA, SARCLISA, Onivyde, IMBRUVICA, clonoSEQ.
Industry payments across CA — which companies pay providers there.
